BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24533716)

  • 1. Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.
    Kim HK; Green JE
    Pharmacogenomics; 2014 Feb; 15(3):375-84. PubMed ID: 24533716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
    Young K; Chau I
    Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
    Wong H; Yau T
    Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure].
    Cheung DY; Kim JK
    Korean J Gastroenterol; 2013 Mar; 61(3):117-27. PubMed ID: 23575230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 testing in gastric cancer: An update.
    Abrahao-Machado LF; Scapulatempo-Neto C
    World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer.
    Carlomagno N; Incollingo P; Tammaro V; Peluso G; Rupealta N; Chiacchio G; Sandoval Sotelo ML; Minieri G; Pisani A; Riccio E; Sabbatini M; Bracale UM; Calogero A; Dodaro CA; Santangelo M
    Biomed Res Int; 2017; 2017():7869802. PubMed ID: 29094049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
    Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
    Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeted therapy for advanced gastric cancer.
    Kim JG
    Korean J Intern Med; 2013 Mar; 28(2):149-55. PubMed ID: 23525404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for gastric cancer.
    Smyth EC; Cunningham D
    Curr Treat Options Oncol; 2012 Sep; 13(3):377-89. PubMed ID: 22552927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for gastric cancer: Current status and future directions (Review).
    Yuan DD; Zhu ZX; Zhang X; Liu J
    Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
    Kim C; Mulder K; Spratlin J
    Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized targeted therapy for lung cancer.
    Wu K; House L; Liu W; Cho WCS
    Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
    Deng N; Goh LK; Wang H; Das K; Tao J; Tan IB; Zhang S; Lee M; Wu J; Lim KH; Lei Z; Goh G; Lim QY; Tan AL; Sin Poh DY; Riahi S; Bell S; Shi MM; Linnartz R; Zhu F; Yeoh KG; Toh HC; Yong WP; Cheong HC; Rha SY; Boussioutas A; Grabsch H; Rozen S; Tan P
    Gut; 2012 May; 61(5):673-84. PubMed ID: 22315472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular-targeted first-line therapy for advanced gastric cancer.
    Song H; Zhu J; Lu D
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011461. PubMed ID: 27432490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.
    Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
    Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
    Jørgensen JT
    World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New advances in targeted gastric cancer treatment.
    Lazăr DC; Tăban S; Cornianu M; Faur A; Goldiş A
    World J Gastroenterol; 2016 Aug; 22(30):6776-99. PubMed ID: 27570417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.